Moreover, the administration of IFN-based therapies was often impeded by the prevalence of hematologic complications, including leukopenia, thrombocytopenia, and anemia, which were attributed to the myelosuppressive effects of IFN [22]. This evidence concerns the gene IFNA1 and anemia (phenotype).